Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine protease 33 is a human protein belonging to the serine protease family of enzymes, encoded by the *PRSS33* gene. Serine proteases are enzymes that cleave peptide bonds in proteins via a serine residue in their active site, and are found widely in both eukaryotes and prokaryotes. PRSS33 is predicted to enable serine-type endopeptidase activity, specifically cleaving substrate peptides before arginine (Arg) residues. It is localized to the cytoplasm and contributes generally to proteolysis—protein degradation—within the cell. An important paralog is PRSS27. While serine proteases as a class have substantial relevance for diseases—including roles in cancer, inflammation, and cardiovascular conditions—the direct role of serine protease 33 (PRSS33) in specific diseases remains to be established. No drugs are known to act specifically on this target, and its clinical significance is not yet defined.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine protease 33 (PRSS33).